<DOC>
	<DOC>NCT01591148</DOC>
	<brief_summary>This study will determine how morbid obesity affects the distribution and metabolism of the drug propofol. The investigators hypothesize that propofol will be distributed and metabolized differently in morbidly obese subjects as compared to normal weight subjects.</brief_summary>
	<brief_title>A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Obesity, Morbid</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<criteria>adult age (ages 1870) body mass index greater than 40 or between 2025 American Society of Anesthesiologists Class I, II, or III undergoing elective surgical procedure requiring general anesthesia evidence of cardiovascular or pulmonary disease kidney or liver dysfunction drug allergy to propofol history of difficult airway on prescribed or over the counter anxiolytics, antipsychotics, or sleeping aids unable to speak or understand English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>